PROTECT: A Randomized Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia Among Anti-Platelet and Anti-Thrombotic Agents

Study of:
This is a randomized, open-label, multi-center study to evaluate 3 different IV blood thinning medications during coronary intervention in high risk patients with unstable angina/non ST elevation heart attack. The primary objective is to determine which medication provides the most improved coronary blood flow immediately following cardiac stenting. Participants who meet eligibility criteria need to be willing to wear a Holter monitor for 72 hours and receive a 48-hour follow-up phone call.

• Jay H. Traverse, MD, FACC, FAHA

• M. Nicholas Burke, MD
• Ivan J. Chavez, MD, FACC
• Timothy D. Henry, MD, FACC
• John R. Lesser, MD, FACC
• Daniel Lips, MD, FACC
• James D. Madison, MD, FACC
• Michael R. Mooney, MD, FACC
• Wesley R. Pedersen, MD, FACC
• Anil K. Poulose, MD, FACC
• Yale Wang, MD, FACC, FSCAI

• Peg Demmer, RN

For more information about this study or the Interventional Cardiology Research program at the Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, please contact Carol Stone at 612-863-9124.